Core Insights - Zhendong Pharmaceutical (300158.SZ) reported its Q3 2025 financial results, revealing that as of October 22, 2025, six institutional investors held a total of 395 million shares, representing 39.33% of the company's total equity [1] - The institutional ownership increased by 0.41 percentage points compared to the previous quarter [1] - The report also noted the presence of 13 public funds, including notable names such as Invesco Great Wall and Huashang, which did not disclose holdings in the previous quarter [1] Institutional Ownership - Six institutional investors collectively own 39.33% of Zhendong Pharmaceutical's shares, with significant contributions from Shanxi Zhendong Health Industry Group and Hong Kong Central Clearing Limited [1] - The increase in institutional ownership indicates growing confidence in the company among institutional investors [1] Public Fund Activity - A total of 13 public funds were reported, including Invesco Great Wall and Huashang, which are focused on enhancing index performance [1] - This suggests a diversified interest from public funds in Zhendong Pharmaceutical, potentially indicating positive market sentiment [1] Social Security Fund Involvement - One new social security fund, the National Social Security Fund 104 Portfolio, disclosed its holdings in Zhendong Pharmaceutical during this reporting period [1] - This addition reflects the interest of social security funds in the company's performance and stability [1] Foreign Investment Trends - Foreign investment increased with Hong Kong Central Clearing Limited raising its stake by 2.93% compared to the previous period [1] - This uptick in foreign investment may signal a favorable outlook for Zhendong Pharmaceutical in the international market [1]